Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

687TiP - A phase I, first in human study of TORL-4-500 in patients with advanced cancer

Date

14 Sep 2024

Session

Poster session 01

Topics

Clinical Research

Tumour Site

Small Cell Lung Cancer

Presenters

Jonathan Goldman

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

J.W. Goldman1, L.S. Rosen1, A. Kung2, A. Romero2, I. Qazi2, H. Dokainish2, S. Letrent2, D. Slamon3

Author affiliations

  • 1 Department Of Medicine, UCLA Hematology/Oncology Santa Monica, 90404 - Santa Monica/US
  • 2 Research And Development Department, TORL Biotherapeutics, LLC, 90230 - Culver City/US
  • 3 Hematology/oncology, UCLA - David Geffen School of Medicine, 90095 - Los Angeles/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 687TiP

Background

Delta-like 1 homolog protein (DLK1), also known as preadipocyte factor 1 (PREF-1) and fetal antigen 1 (FA1), is a transmembrane protein and an inhibitor of NOTCH1 signaling. It modulates a wide range of developmental processes where NOTCH signaling is critical including cellular proliferation, cell fate, and terminal differentiation. As a result of its role in developmental signaling, expression of DLK1 decreases as development proceeds, with limited expression in adult tissues, with the exception of adrenal and pituitary glands, and ovaries. DLK1 is highly expressed in several cancers, including adrenocortical, uterine, and testicular cancers as well as a subset of pancreatic, sarcoma, liver, and lung cancers. Taken together, this expression profile makes DLK1 an attractive candidate for targeted therapeutic approaches. TORL-4-500 is an antibody-drug conjugate (ADC) with a fully humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) selective for DLK1 linked to monomethyl auristatin E (MMAE), an anti-mitotic agent via a cathepsin hydrolysable dipeptide valine-citrulline (vc) linker.

Trial design

TORL-4-500-001 is a two-part first in human study to characterize the safety, tolerability, and dose-limiting toxicities (DLT) and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of TORL-4-500 administered as monotherapy intravenously Q3W in patients with advanced cancer. Serum PK, immunogenicity, and antitumor activity will also be evaluated. Endpoints include frequency and severity of adverse events and objective response rate (ORR) based on RECIST v1.1 criteria. Correlative biomarker studies will evaluate the relationship of clinical benefit with blood and tissue biomarkers. This study is currently open with patients enrolling in dose escalation. Once the RP2D is established, dose expansion in DLK1+ indication-specific cohorts will commence.

Clinical trial identification

NCT06005740.

Editorial acknowledgement

Legal entity responsible for the study

TORL Biotherapeutics.

Funding

TORL Biotherapeutics.

Disclosure

J.W. Goldman: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: Genentech, Eli Lilly, Janssen, AbbVie, Gritstone; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Eli Lilly; Financial Interests, Institutional, Local PI: Genentech, Janssen, BMS, AbbVie. L.S. Rosen: Financial Interests, Institutional, Funding, PI at UCLA Health Hem/Onc for Inspirna trial, Institution receives research funding: Inspirna. A. Kung, A. Romero, I. Qazi, H. Dokainish, S. Letrent: Financial Interests, Personal, Stocks/Shares: TORL Bio. D. Slamon: Financial Interests, Personal and Institutional, Member of Board of Directors: TORL Bio.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.